Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for lung cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Fruquintinib After Two Prior Chemotherapy Regimens in Chinese Patients With Advanced Nonsquamous NonSmall-Cell LungCancer 29528793 2018 04 17 1527-7755 36 12 2018 Apr 20 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Fruquintinib After Two Prior Chemotherapy Regimens in Chinese (...) Patients With Advanced Nonsquamous Non‒Small-Cell LungCancer. 1207-1217 10.1200/JCO.2017.76.7145 Purpose Patients with advanced non‒small-cell lungcancer (NSCLC) who fail two lines of chemotherapy have unmet medical needs. The kinase inhibitor fruquintinib selectively targets vascular endothelial growth factor receptors and, hence, tumor angiogenesis and lymphogenesis. This randomized, double-blind, placebo-controlled, multicenter phase II trial evaluated the efficacy and safety of fruquintinib
Identifying Patients for Whom LungCancer Screening is Preference-Sensitive: A Microsimulation Study. Background: Many health systems are exploring how to implement low-dose computed tomography (LDCT) screening programs that are effective and patient-centered. Objective: To examine factors that influence when LDCT screening is preference-sensitive. Design: State-transition microsimulation model. Data Sources: Two large randomized trials, published decision analyses, and the SEER (Surveillance (...) , Epidemiology, and End Results) cancer registry. Target Population: U.S.-representative sample of simulated patients meeting current U.S. Preventive Services Task Force criteria for screening eligibility. Time Horizon: Lifetime. Perspective: Individual. Intervention: LDCT screening annually for 3 years. Outcome Measures: Lifetime quality-adjusted life-year gains and reduction in lungcancer mortality. To examine the effect of preferences on net benefit, disutilities (the "degree of dislike") quantifying
Higher LungCancer Incidence in Young Women Than Young Men in the United States. BACKGROUND: Previous studies showed a higher incidence of lungcancer among young women than among young men in the United States. Whether this pattern has continued in contemporary birth cohorts and, if so, whether it can be fully explained by sex differences in smoking behaviors are unknown. METHODS: We examined the nationwide population-based incidence of lungcancer according to sex, race or ethnic group, age (...) group (30 to 34, 35 to 39, 40 to 44, 45 to 49, and 50 to 54 years), year of birth (1945 to 1980), and calendar period of diagnosis (1995-1999, 2000-2004, 2005-2009, and 2010-2014), and we calculated female-to-male incidence rate ratios. We also examined the prevalence of cigarette smoking, using data from the National Health Interview Survey from 1970 to 2016. RESULTS: Over the past two decades, the age-specific incidence of lungcancer has generally decreased among both men and women 30 to 54 years
Implications of Nine Risk Prediction Models for Selecting Ever-Smokers for Computed Tomography LungCancer Screening. Background: Lungcancer screening guidelines recommend using individualized risk models to refer ever-smokers for screening. However, different models select different screening populations. The performance of each model in selecting ever-smokers for screening is unknown. Objective: To compare the U.S. screening populations selected by 9 lungcancer risk models (the Bach model (...) ; the Spitz model; the Liverpool Lung Project [LLP] model; the LLP Incidence Risk Model [LLPi]; the Hoggart model; the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Model 2012 [PLCOM2012]; the Pittsburgh Predictor; the LungCancer Risk Assessment Tool [LCRAT]; and the LungCancer Death Risk Assessment Tool [LCDRAT]) and to examine their predictive performance in 2 cohorts. Design: Population-based prospective studies. Setting: United States. Participants: Models selected U.S. screening
Nivolumab plus Ipilimumab in LungCancer with a High Tumor Mutational Burden. Background Nivolumab plus ipilimumab showed promising efficacy for the treatment of non-small-cell lungcancer (NSCLC) in a phase 1 trial, and tumor mutational burden has emerged as a potential biomarker of benefit. In this part of an open-label, multipart, phase 3 trial, we examined progression-free survival with nivolumab plus ipilimumab versus chemotherapy among patients with a high tumor mutational burden (≥10 (...) mutations per megabase). Methods We enrolled patients with stage IV or recurrent NSCLC that was not previously treated with chemotherapy. Those with a level of tumor programmed death ligand 1 (PD-L1) expression of at least 1% were randomly assigned, in a 1:1:1 ratio, to receive nivolumab plus ipilimumab, nivolumab monotherapy, or chemotherapy; those with a tumor PD-L1 expression level of less than 1% were randomly assigned, in a 1:1:1 ratio, to receive nivolumab plus ipilimumab, nivolumab plus
Neoadjuvant PD-1 Blockade in Resectable LungCancer. Background Antibodies that block programmed death 1 (PD-1) protein improve survival in patients with advanced non-small-cell lungcancer (NSCLC) but have not been tested in resectable NSCLC, a condition in which little progress has been made during the past decade. Methods In this pilot study, we administered two preoperative doses of PD-1 inhibitor nivolumab in adults with untreated, surgically resectable early (stage I, II, or IIIA) NSCLC (...) . Nivolumab (at a dose of 3 mg per kilogram of body weight) was administered intravenously every 2 weeks, with surgery planned approximately 4 weeks after the first dose. The primary end points of the study were safety and feasibility. We also evaluated the tumor pathological response, expression of programmed death ligand 1 (PD-L1), mutational burden, and mutation-associated, neoantigen-specific T-cell responses. Results Neoadjuvant nivolumab had an acceptable side-effect profile and was not associated
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell LungCancer. Background First-line therapy for advanced non-small-cell lungcancer (NSCLC) that lacks targetable mutations is platinum-based chemotherapy. Among patients with a tumor proportion score for programmed death ligand 1 (PD-L1) of 50% or greater, pembrolizumab has replaced cytotoxic chemotherapy as the first-line treatment of choice. The addition of pembrolizumab to chemotherapy resulted in significantly higher rates (...) of response and longer progression-free survival than chemotherapy alone in a phase 2 trial. Methods In this double-blind, phase 3 trial, we randomly assigned (in a 2:1 ratio) 616 patients with metastatic nonsquamous NSCLC without sensitizing EGFR or ALK mutations who had received no previous treatment for metastatic disease to receive pemetrexed and a platinum-based drug plus either 200 mg of pembrolizumab or placebo every 3 weeks for 4 cycles, followed by pembrolizumab or placebo for up to a total of 35
Postoperative radiotherapy reduces survival after surgery to remove non-small cell lungcancer NIHR DC | Signal - Postoperative radiotherapy reduces survival after surgery to remove non-small cell lungcancer Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal Postoperative radiotherapy reduces survival after surgery to remove non-small cell lungcancer Published on 28 February 2017 Postoperative radiotherapy increases the risk of death by 18% for patients with non-small cell lung (...) a detrimental effect on survival and cancer recurrence rates. Most of the trials are from over 30 years ago, so there is the possibility that newer radiotherapy techniques may be less harmful. Nevertheless, this review provides the best evidence to date that postoperative radiotherapy may not be appropriate as a routine treatment for non-small cell lungcancer. Why was this study needed? Lungcancer is the second most common cancer in the UK with 37,453 new cases registered in 2014. The majority of lung
Whole brain radiotherapy provides little benefit for lungcancer that has spread NIHR DC | Signal - Whole brain radiotherapy provides little benefit for lungcancer that has spread Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal Whole brain radiotherapy provides little benefit for lungcancer that has spread Published on 10 January 2017 Radiotherapy to the whole brain makes little difference to people with the commonest type of lungcancer that has spread to the brain (...) and cannot be operated on. This mainly UK-based trial found no difference in overall survival and quality of life among people who had whole brain radiotherapy plus usual supportive care compared with people who received supportive care alone. This is the largest trial to assess the effect of this treatment in people with non-small cell lungcancer and multiple brain metastases (cancer deposits in the brain). Practice has been changing since early results of the trial were released. The final results
Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell LungCancer 29293386 2018 01 19 1527-7755 2018 Jan 02 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell LungCancer. JCO2017740720 (...) 10.1200/JCO.2017.74.0720 Purpose This randomized trial compared outcomes of passive scattering proton therapy (PSPT) versus intensity-modulated (photon) radiotherapy (IMRT), both with concurrent chemotherapy, for inoperable non-small-cell lungcancer (NSCLC). We hypothesized that PSPT exposes less lung tissue to radiation than IMRT and thereby reduces toxicity without compromising tumor control. The primary end points were grade ≥ 3 radiation pneumonitis (RP) and local failure (LF). Patients
Ceritinib (Zykadia) - anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lungcancer Published 9 April 2018 Statement of Advice: ceritinib 150mg hard capsules (Zykadia ® ) SMC No 1333/18 Novartis Pharmaceuticals UK Ltd 9 March 2018 ADVICE: in the absence of a submission from the holder of the marketing authorisation ceritinib (Zykadia ® ) is not recommended for use within NHS Scotland. Indication under review: As monotherapy for the first-line treatment of adult patients (...) with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lungcancer. The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland. Advice context: No part of this advice may be used without the whole of the advice being quoted in full. This advice represents the view of the Scottish Medicines Consortium. It is provided to inform the considerations of Area Drug & Therapeutics
Long nonâ€coding RNA linc01433 promotes migration and invasion in nonâ€small cell lungcancer ORIGINAL ARTICLE Long non-coding RNA linc01433 promotes migration and invasion in non-small cell lungcancer Banglun Qian 1 , Xiang Wang 1 , Chao Mao 2,3 , Yiqun Jiang 2,3 , Ying Shi 2,3 , Ling Chen 2,3 , Shuang Liu 4 , Bin Wang 1 , ShuPan 1 , Yongguang Tao 1,2,3,4* & Hongcan Shi 5* 1 Department of Thoracic Surgery, Second Xiangya Hospital of Central South University, Hunan, China 2 Key Laboratory (...) . Received: 24 January 2018; Accepted: 8 February 2018. doi: 10.1111/1759-7714.12623 Thoracic Cancer 9 (2018) 589–597 Abstract Background: For many years, lungcancer has been the most common and deadly cancer worldwide. Early diagnosis of non-small cell lungcancer (NSCLC) in particular is very dif?cult because the symptoms are often ignored. The ?ve- year survival rate is very low despite great improvements to therapy. Thus, there is an urgent need to identify prognostic biomarkers and target molecules